Anticancer Potential of Oleandrin: Preclinical Mechanisms, Botanical Origins, and Pharmacokinetic Insights
Journal of Phytochemical Insights · 2025
DOI: 10.71193/jpci.20250010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Phytochemical Insights, 2025. Verfasst von Maisa Rahman und 4 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Oleandrin (OLD) is a lipid-soluble cardiac glycoside derived mainly from the leaves of Nerium oleander (Apocynaceae), traditionally used in herbal medicine. Among the various parts of the plant, the leaves contain the highest concentration of OLD. Red-flowered varieties contain higher levels of cardiac glycosides. Although Thevetia peruviana (yellow oleander) belongs to the same family, it does not produce OLD. Recent studies show that OLD has significant anticancer potential against various cancers such as breast, prostate, lung, colon, pancreatic, endometrial cancers, melanoma, and osteosarcoma. It works by inducing apoptosis (programmed cell death) via caspase activation, arresting the cell cycle, reducing oxidative stress, and lowering mitochondrial membrane potential. These actions are regulated by key signaling pathways including Wnt/β-catenin, phosphatidylinositol 3-kinase/protein kinase B/nuclear factor-kappa B (PI3K/Akt/NF-κB), and extracellular signal-regulated kinase (ERK). Pharmacokinetic studies reveal that OLD is rapidly absorbed through the oral mucosa and gastrointestinal tract, crosses the blood-brain barrier, and has a half-life of about 2.3 hours. It is mainly metabolized in the liver and intestine, and excreted mostly through feces (66%) and partly through urine (8%). Due to its strong anticancer mechanisms, OLD shows promise as a novel anticancer agent. However, further in vivo studies and clinical trials are necessary to confirm its therapeutic efficacy and safety in humans. Future research should also focus on optimizing its pharmacokinetic properties and minimizing toxicity to enable its transition from experimental models to clinical application.
Zitieren
APA
Rahman, M., Shadin, M., Sultana, J., Hosain, M. S., & Oni, M. I. J. (2025). Anticancer Potential of Oleandrin: Preclinical Mechanisms, Botanical Origins, and Pharmacokinetic Insights. Journal of Phytochemical Insights. https://doi.org/10.71193/jpci.20250010
Vancouver
Rahman M, Shadin M, Sultana J, Hosain MS, Oni MIJ. Anticancer Potential of Oleandrin: Preclinical Mechanisms, Botanical Origins, and Pharmacokinetic Insights. Journal of Phytochemical Insights. 2025. doi:10.71193/jpci.20250010
BibTeX
@article{Rahman2025,
author = {Rahman, Maisa and Shadin, Md. and Sultana, Jakia and Hosain, Md Sabbir and Oni, Most. Israt Jahan},
title = {Anticancer Potential of Oleandrin: Preclinical Mechanisms, Botanical Origins, and Pharmacokinetic Insights},
journal = {Journal of Phytochemical Insights},
year = {2025},
doi = {10.71193/jpci.20250010}
}
EUVIMED